These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21118736)

  • 1. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients.
    Kuypers DR; de Jonge H; Naesens M; Vanrenterghem Y
    Clin Ther; 2010 Nov; 32(12):2012-23. PubMed ID: 21118736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
    Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.
    Metalidis C; Lerut E; Naesens M; Kuypers DR
    Transplantation; 2011 May; 91(10):1098-102. PubMed ID: 21544031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
    Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
    Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients.
    Anutrakulchai S; Pongskul C; Kritmetapak K; Limwattananon C; Vannaprasaht S
    Br J Clin Pharmacol; 2019 Sep; 85(9):1964-1973. PubMed ID: 31077425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
    van Gelder T; Hesselink DA
    Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
    Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
    Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
    Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y
    Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
    Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
    de Jonge H; de Loor H; Verbeke K; Vanrenterghem Y; Kuypers DR
    Clin Pharmacol Ther; 2011 Sep; 90(3):414-22. PubMed ID: 21753749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients.
    Min SI; Kim SY; Ahn SH; Min SK; Kim SH; Kim YS; Moon KC; Oh JM; Kim SJ; Ha J
    Transplantation; 2010 Dec; 90(12):1394-400. PubMed ID: 21076384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.
    Chen JS; Li LS; Cheng DR; Ji SM; Sun QQ; Cheng Z; Wen JQ; Sha GZ; Liu ZH
    Transplant Proc; 2009 Jun; 41(5):1557-61. PubMed ID: 19545678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors.
    de Denus S; Zakrzewski M; Barhdadi A; Leblanc MH; Racine N; Bélanger F; Carrier M; Ducharme A; Dubé MP; Turgeon J; White M
    J Heart Lung Transplant; 2011 Mar; 30(3):326-31. PubMed ID: 21094057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients.
    Spierings N; Holt DW; MacPhee IA
    Ther Drug Monit; 2013 Jun; 35(3):328-31. PubMed ID: 23666583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients.
    de Jonge H; Metalidis C; Naesens M; Lambrechts D; Kuypers DR
    Pharmacogenomics; 2011 Sep; 12(9):1281-91. PubMed ID: 21770725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.